Aiforia
Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) develops CE-IVD marked deep learning AI solutions for digital pathology, serving clinical laboratories, pharmaceutical and biotech firms, and academic medical centers across Europe, North America, and select Asia-Pacific markets.
- Company typePublic
- Founded2013
- HeadquartersHelsinki, Finland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Aiforia does
Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) is a Finland-based public company founded in 2013 that develops deep learning AI solutions for digital pathology image analysis. The company sells a portfolio of CE-IVD marked clinical AI applications covering breast cancer (Ki-67, HER2, ER/PR scoring), lung cancer (PD-L1), prostate cancer biopsy analysis, gastric cancer, colorectal cancer (QuantCRC prognostic tool), and lymph node metastasis detection. These clinical applications run on a proprietary Foundation Engine designed for robust operation across variable sample quality, staining, and scanner conditions, and are delivered through the cloud-based Aiforia Platform with an integrated Clinical Suite Viewer. Aiforia also offers Aiforia Create, a collaborative cloud environment that allows pathologists and scientists to train custom deep learning models without prior AI expertise, alongside research solutions for preclinical and academic workflows and a veterinary diagnostics offering.
Revenue is generated primarily through annual and multi-year subscriptions for clinical AI deployments and research platform access, supplemented by professional services for enterprise implementations. Pricing is quote-based and tied to deployment scale, user counts, and integration requirements. The company pursues a dual go-to-market of direct enterprise field sales (targeting hospital pathology departments, academic medical centers, and pharma/biotech customers such as AP-HP, Mayo Clinic, Sanofi, Boehringer Ingelheim, and Charles River Laboratories) and channel partnerships with major healthcare IT vendors (Siemens Healthineers, Dedalus Group, Proscia, Tribun Health) plus regional partners in Canada (Quorum Technologies) and South Korea (Urban Datalab). The company maintains wholly-owned subsidiaries in France (Paris) and the United States (Cambridge, MA) to support European and North American commercial operations.
The company holds ISO 13485, ISO 27001, SOC 2 Type II, IVDR, GDPR, and HIPAA-aligned certifications and operates with a headcount of 51-100 employees. Management has disclosed a target of 50 clinical accounts and financial independence by end of 2027, alongside an ambition to cover approximately 80% of pathologists' diagnostic workflow by 2030.
Aiforia firmographics
Firmographics- Name
- Aiforia
- Legal name
- Aiforia Technologies Oyj
- Website
- https://aiforia.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) develops CE-IVD marked deep learning AI solutions for digital pathology, serving clinical laboratories, pharmaceutical and biotech firms, and academic medical centers across Europe, North America, and select Asia-Pacific markets.
- Ownership category
- akta.pro rank
Aiforia industry classification
Industry- Product category
- Digital Pathology AI Software
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Aiforia is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices3 records
Markets served
Aiforia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical AI Solutions Subscription: SaaS subscription model providing access to CE-IVD marked AI diagnostic applications for clinical pathology laboratories. Revenue generated through software subscriptions with recurring annual or multi-year billing.
- Research Solutions Platform: Aiforia Create platform access for pharmaceutical researchers, biotech companies, and academic institutions to develop and deploy custom AI models for preclinical and clinical research applications.
- Professional Services: Implementation, training, and support services for enterprise deployments, particularly through strategic partnerships with Siemens Healthineers and Dedalus.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise clinical subscription |
| Subscription | Annual | Research platform subscription |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels8 records
Aiforia product offering
Product offeringCore offering
Aiforia develops and sells cloud-based deep learning AI software for digital pathology image analysis. Its offering consists of two main product lines: (1) CE-IVD marked Clinical Suites providing AI-driven diagnostic workflows for breast, lung, prostate, gastric, and colorectal cancer plus lymph node metastasis detection, and (2) Research Solutions including the Aiforia Create no-code AI model development platform for preclinical, pharmaceutical, and academic research. Both are powered by the proprietary Foundation Engine and delivered as SaaS to pathology laboratories, pharmaceutical/biotech companies, and academic medical centers.
Product overview
Aiforia offers a cloud-based AI platform for digital pathology with two main product lines: Clinical Solutions (CE-IVD marked AI diagnostic applications) and Research Solutions (for preclinical/academic use). The Clinical Suite portfolio includes specialized AI solutions for breast cancer, lung cancer, prostate cancer, gastric cancer, colorectal cancer (QuantCRC), and lymph node metastasis detection—all powered by the proprietary Foundation Engine technology. Aiforia® Create serves as the AI development tool enabling users to build custom deep learning models without coding. The platform integrates with various laboratory information systems and image management platforms through APIs and partnerships with Dedalus, Proscia, Siemens Healthineers, and Tribun Health.
Differentiator
Problem solved
Functional benefit
Brands
- Aiforia® Clinical Suites: CE-IVD marked AI solutions for clinical diagnostics including Breast Cancer Suite, Lung Cancer Suite, Prostate Cancer Suite, Gastric Suite, and Lymph Node Metastasis detection
- Aiforia® Create
- Aiforia® Platform
- Aiforia® Foundation Engine
- Aiforia® Prostate Cancer Biopsy
- Aiforia® Clinical Suite Viewer
- QuantCRC
Products and services
- Aiforia Clinical Suites Comprehensive portfolio of CE-IVD marked AI solutions for clinical diagnostics in digital pathology, providing fully automated case-centric workflows with a wide range of AI models and an optimized interactive user interface for pathology laboratories.
- Aiforia Breast Cancer Suite
Quantifiable outcome
- Clinical sector revenue grew 68% year-over-year in Q4 2025
- +4 more outcomes
Companies that use Aiforia
Customer profileNamed customers16 records
Segments4 records
Ideal customer profiles4 records
Aiforia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature4 records
Aiforia partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and regional.
- AP-HP (Assistance Publique-Hôpitaux de Paris)flagshipAiforia selected as AI partner for the PROSTIA project led by AP-HP, deploying its CE-IVD-marked prostate cancer diagnostic solution across AP-HP pathology sites. Project expands from 2 hospitals (Bicêtre and Saint-Louis) to 7 total sites, covering all 3,000 prostate biopsy cases per year. Two-year initiative funded by Bpifrance through France 2030 program to evaluate medical, operational, and economic impacts of AI in pathology workflows.
- ProsciacoreNon-exclusive partnership integrating Aiforia's AI-powered diagnostic applications with Proscia's Concentriq platform, enabling seamless AI-driven digital pathology workflows for anatomic pathology laboratories globally. Both companies have joined Proscia's Ready partner alliance and will showcase innovations at USCAP 115th Annual Meeting in March 2026.
- Siemens HealthineerscoreStrategic partnership with Siemens Healthineers to expand availability of Aiforia's AI applications for clinical diagnostics across European diagnostic laboratories. Siemens Healthineers affiliates will co-market and sell Aiforia's digital pathology solutions as part of their broader portfolio, leveraging their strong regional presence and integration capabilities.
- Dedalus GroupcoreStrategic alliance to integrate Aiforia's AI solutions into Dedalus' InVitro Anatomic Pathology Information System. The partnership aims to accelerate adoption of Aiforia's AI solutions among Dedalus' existing customer base of 5,700 laboratories and diagnostic centers worldwide by providing ready-made integration.
- Quorum TechnologiesregionalPartnership to expand AI-assisted pathology solutions in Canada, improving digital pathology workflows and enhancing patient care by making AI solutions more accessible in the Canadian healthcare sector.
- Urban DatalabregionalPartnership to promote AI-based digital pathology in South Korea, improving diagnostic accuracy, workflow efficiency, and patient care across South Korean hospitals.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Aiforia competitors and assessment
Company assessmentDirect peers
- Paige.AI: Pure-play AI digital pathology company offering FDA-authorized clinical AI solutions and a research platform. Directly comparable to Aiforia in target market (clinical pathology labs and pharma), technology (deep learning on whole-slide images), and business model (SaaS subscriptions).
- Ibex Medical Analytics: AI-powered cancer diagnostics platform for pathology, with CE-marked clinical products deployed across European hospitals. Closely comparable to Aiforia in CE-IVD clinical product portfolio, channel partnerships with tier-1 diagnostics vendors, and target customer segments.
- PathAI: AI pathology company combining diagnostic products with biopharma services. Comparable to Aiforia across clinical AI applications, research/AI development tools (AISight), and pharmaceutical R&D use cases.
- Owkin: AI-for-drug-discovery and pathology company serving both biopharma and clinical diagnostic customers. Comparable to Aiforia in using deep learning on pathology images for both pharma research and clinical decision support.
Emerging players
- Proscia: Digital pathology platform vendor whose Concentriq platform integrates with Aiforia's AI solutions. Both partner and partial competitor with overlapping enterprise pathology customer base and cloud-based delivery model.
- Tribun Health: Digital pathology image management vendor (CaloPix) that integrates with Aiforia through CaloPix Connect. Adjacent competitor and integration partner in enterprise pathology workflows.
- Indica Labs: Pathology image analysis software vendor with both research (Halo) and emerging clinical offerings. Comparable in serving pharma and academic research customers and providing quantitative AI image analysis tooling.
Broad incumbents
- Roche (Ventana Digital Pathology): Global diagnostics incumbent with a broad digital pathology portfolio spanning hardware, software, and AI. Comparable as a broader competitor with much greater scale and ability to bundle AI offerings with installed hardware base.
- Philips Digital Pathology: Healthcare technology incumbent with IntelliSite digital pathology solution. Comparable as an enterprise-scale alternative that bundles whole-slide imaging, workflow software, and AI applications across hospital systems.
- Leica Biosystems (Danaher): Major pathology equipment and software vendor (Aperio) now part of Danaher's diagnostics platform. Comparable as an established competitor in clinical pathology workflow infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Aiforia social profiles
Digital presenceAiforia compliance and trust
Trust signalCompliance6 records
Aiforia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aiforia leadership team
Management profileNumber of profiles
Profiles17 records
Aiforia subsidiaries and ownership
Company hierarchySubsidiaries2 records
Aiforia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aiforia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aiforia
What does Aiforia do?
Aiforia develops and sells cloud-based deep learning AI software for digital pathology image analysis. Its offering consists of two main product lines: (1) CE-IVD marked Clinical Suites providing AI-driven diagnostic workflows for breast, lung, prostate, gastric, and colorectal cancer plus lymph node metastasis detection, and (2) Research Solutions including the Aiforia Create no-code AI model development platform for preclinical, pharmaceutical, and academic research. Both are powered by the proprietary Foundation Engine and delivered as SaaS to pathology laboratories, pharmaceutical/biotech companies, and academic medical centers.
Is Aiforia a public or private company?
Aiforia is a public company. It is classified as public and is currently operating.
When was Aiforia founded?
Aiforia was founded in 2013. It employs 51 to 100 people.
Where is Aiforia based?
Aiforia is headquartered in Helsinki, Finland, in the Europe region.
How does Aiforia make money?
Three revenue lines are on record. Clinical AI Solutions Subscription is the primary driver. The others are research Solutions Platform and professional Services.
Who are Aiforia's main competitors?
Direct peers on record are Paige.AI, Ibex Medical Analytics, PathAI and Owkin. Emerging players are Proscia, Tribun Health and Indica Labs. Broad incumbents are Roche (Ventana Digital Pathology), Philips Digital Pathology and Leica Biosystems (Danaher).
Does Aiforia have an API?
No public API is recorded for Aiforia.
What industry is Aiforia in?
Aiforia's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.